Palau Pharma S.A. ("Palau") is a product-driven biopharmaceutical company focused on the discovery and development of medicines that are designed to address the unmet needs of patients suffering from inflammatory and autoimmune diseases. By successfully targeting specific conditions that are currently underserved, we are able to open up opportunities for commercializing best-in-class or first-in-class products.

In addition to our unique focus, we adopt a nimble approach and operating structure that emphasizes the importance of developing safe and effective products within an expedited framework. This approach has been strongly validated through partnering agreements with broad range of companies, including GlaxoSmithKline, Schering-Plough, Affectis Pharmaceuticals, IberHospitex, and others.

Palau commenced operations in 2006 as a spin-out of Grupo Uriach's R&D Unit with the capitalization of five external investors: Caixa Catalunya, Caja Duero, Najeti Capital, Andosins Capital and Palau's senior management. Our R&D track record, strategy and partner validated business model position the company to become a leading innovator in the European biopharmaceutical industry.

Our state-of-the-art facilities and prime location on the outskirts of Barcelona are ideal for creating the professional, productive and positive environment needed to achieve our scientific and business goals.